Brian Hoyle, PhD | Authors


Prevention of Cytomegalovirus After Allogeneic HSCT

April 26, 2018

Two poster presentations at the 2018 BMT Tandem Meetings of the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation, provided a compelling extension of the recent phase III clinical trial that demonstrated the efficacy of prophylactic therapy with letermovir (Prevymis) for the prevention of cytomeg alovirus (CMV) infection in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).